Cardiol Therapeutics Inc. (CRDL)
USD 0.97
(-0.52%)
USD 0.97
(-0.52%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 158.53 Thousand CAD | 139.24% |
| 2022 | 72.87 Thousand CAD | -38.02% |
| 2021 | 117.57 Thousand CAD | -24.9% |
| 2020 | 156.56 Thousand CAD | -17.92% |
| 2019 | 190.75 Thousand CAD | -29.15% |
| 2018 | 269.21 Thousand CAD | 41.66% |
| 2017 | 190.04 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 164.27 Thousand CAD | -1.71% |
| 2024 Q1 | 167.13 Thousand CAD | -4.13% |
| 2023 Q4 | 174.34 Thousand CAD | -3.79% |
| 2023 Q2 | 48.19 Thousand CAD | -20.55% |
| 2023 Q1 | 60.66 Thousand CAD | -16.75% |
| 2023 FY | 174.34 Thousand CAD | 139.24% |
| 2023 Q3 | 181.2 Thousand CAD | 275.99% |
| 2022 Q2 | 96.4 Thousand CAD | -10.1% |
| 2022 Q3 | 84.77 Thousand CAD | -12.07% |
| 2022 FY | 72.87 Thousand CAD | -38.02% |
| 2022 Q1 | 107.23 Thousand CAD | -8.79% |
| 2022 Q4 | 72.87 Thousand CAD | -14.04% |
| 2021 Q1 | 147.1 Thousand CAD | -6.05% |
| 2021 FY | 117.57 Thousand CAD | -24.9% |
| 2021 Q4 | 117.57 Thousand CAD | -7.88% |
| 2021 Q3 | 127.63 Thousand CAD | -7.15% |
| 2021 Q2 | 137.45 Thousand CAD | -6.55% |
| 2020 Q1 | 182.96 Thousand CAD | -4.08% |
| 2020 FY | 156.56 Thousand CAD | -17.92% |
| 2020 Q4 | 156.56 Thousand CAD | -5.54% |
| 2020 Q3 | 165.74 Thousand CAD | -5.14% |
| 2020 Q2 | 174.71 Thousand CAD | -4.51% |
| 2019 Q3 | 198.31 Thousand CAD | -2.4% |
| 2019 Q2 | 203.19 Thousand CAD | 0.0% |
| 2019 Q1 | - CAD | -100.0% |
| 2019 FY | 190.75 Thousand CAD | -29.15% |
| 2019 Q4 | 190.75 Thousand CAD | -3.82% |
| 2018 Q4 | 269.21 Thousand CAD | -97.86% |
| 2018 FY | 269.21 Thousand CAD | 41.66% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 Q2 | 10.05 Million CAD | 0.0% |
| 2018 Q3 | 12.57 Million CAD | 25.13% |
| 2017 FY | 190.04 Thousand CAD | 0.0% |
| 2017 Q4 | 190.04 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alvotech | 1.07 Billion USD | 99.985% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.976% |
| Journey Medical Corporation | 17.73 Million USD | 99.106% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.938% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 99.064% |
| PainReform Ltd. | 86 Thousand USD | -84.34% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 75.896% |
| SCYNEXIS, Inc. | 15.08 Million USD | 98.949% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | 75.896% |
| Bright Green Corporation | 1.85 Million USD | 91.439% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.971% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 99.84% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.95% |
| Alpha Teknova, Inc. | 30.45 Million USD | 99.48% |
| Embecta Corp. | 1.63 Billion USD | 99.99% |
| Safety Shot Inc | 1.54 Million USD | 89.765% |
| Procaps Group, S.A. | 285.93 Million USD | 99.945% |
| Cosmos Health Inc. | 12.42 Million USD | 98.724% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | 94.012% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.973% |
| Theratechnologies Inc. | 58.96 Million USD | 99.731% |
| Harrow Health, Inc. | 190.5 Million USD | 99.917% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | 73.926% |
| Biofrontera Inc. | 5.39 Million USD | 97.064% |
| DURECT Corporation | 20.74 Million USD | 99.236% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 99.618% |
| Cronos Group Inc. | 2.53 Million USD | 93.758% |
| OptiNose, Inc. | 131.74 Million USD | 99.88% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.978% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 99.564% |
| RedHill Biopharma Ltd. | 1.17 Million USD | 86.485% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 99.867% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 99.14% |
| Radius Health, Inc. | 365.31 Million USD | 99.957% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 97.108% |
| ProPhase Labs, Inc. | 21.38 Million USD | 99.259% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.97% |
| Procaps Group S.A. | 285.93 Million USD | 99.945% |
| TherapeuticsMD, Inc. | 8 Million USD | 98.02% |
| Viatris Inc. | 18.12 Billion USD | 99.999% |
| Rockwell Medical, Inc. | 13.43 Million USD | 98.82% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 98.952% |
| SIGA Technologies, Inc. | 1.46 Million USD | 89.171% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.959% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 99.878% |
| Shineco, Inc. | 29.65 Million USD | 99.465% |
| PetIQ, Inc. | 468.3 Million USD | 99.966% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -165.073% |
| Incannex Healthcare Limited | 373 Thousand USD | 57.498% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.963% |
| Alimera Sciences, Inc. | 67.39 Million USD | 99.765% |
| Assertio Holdings, Inc. | 40.91 Million USD | 99.613% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | 85.425% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 98.085% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | 92.404% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 84.655% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 99.552% |
| Hempacco Co., Inc. | 13.72 Million USD | 98.845% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 99.985% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | 99.746% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.974% |
| Currenc Group, Inc. | 31.94 Million USD | 99.504% |
| Kamada Ltd. | 8.74 Million USD | 98.188% |
| Indivior PLC | 281.6 Million USD | 99.944% |
| Evoke Pharma, Inc. | 5 Million USD | 96.829% |
| Flora Growth Corp. | 3.67 Million USD | 95.683% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 84.655% |
| Evolus, Inc. | 126.54 Million USD | 99.875% |
| HUTCHMED (China) Limited | 86.13 Million USD | 99.816% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.975% |
| Akanda Corp. | 3.99 Million USD | 96.036% |